|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
Los Angeles, Los Angeles, CA 90064, US
|
|
Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
|
Immix Biopharma (Nasdaq: IMMX) Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Immix Biopharma (Nasdaq: IMMX) email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Immix Biopharma (Nasdaq: IMMX) customer service number call here +1 (888) 958-1084. To contact Immix Biopharma (Nasdaq: IMMX) customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.